Literature DB >> 16720054

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.

Takashi Iwai1, Satoshi Ito, Kahori Tanimitsu, Shunichi Udagawa, Jun-Ichiro Oka.   

Abstract

Glia play an important role in neurotoxicity in neurodegenerative diseases. In this study, we investigated the expression of glucagon-like peptide-1 (GLP-1) and its receptor, and the effects of GLP-1 on lipopolysaccharide (LPS)-induced IL-1beta mRNA expression and IL-1beta production in glia. GLP-1-like immunoreactivity was observed in amoeboid microglia, but not ramified microglia or astrocytes. GLP-1 binding and GLP-1 receptor mRNA expression were observed in both astrocytes and microglia. GLP-1-induced morphological changes in microglia from the ramified type to the amoeboid type, suggesting an increase in production and release of endogenous GLP-1. GLP-1 prevented the LPS-induced IL-1beta mRNA expression, which effect was, in turn, inhibited by pretreatment with SQ22536, an adenylate cyclase inhibitor. GLP-1 also increased cAMP concentration and cAMP response element-binding protein phosphorylation in astrocytes. These results suggest that GLP-1 may be a modulator of inflammation in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720054     DOI: 10.1016/j.neures.2006.04.008

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  72 in total

1.  The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.

Authors:  Y Diz-Chaves; L Toba; J Fandiño; L C González-Matías; L M Garcia-Segura; F Mallo
Journal:  J Neuroinflammation       Date:  2018-12-05       Impact factor: 8.322

2.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Authors:  F Vittone; A Liberman; D Vasic; R Ostertag; M Esser; D Walcher; A Ludwig; N Marx; M Burgmaier
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

3.  The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.

Authors:  Rodrigo B Mansur; Gabriel R Fries; Alisson P Trevizol; Mehala Subramaniapillai; Julie Lovshin; Kangguang Lin; Maj Vinberg; Roger C Ho; Elisa Brietzke; Roger S McIntyre
Journal:  Eur Neuropsychopharmacol       Date:  2018-11-06       Impact factor: 4.600

4.  Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

Authors:  Miaad Bader; Yazhou Li; Daniela Lecca; Vardit Rubovitch; David Tweedie; Elliot Glotfelty; Lital Rachmany; Hee Kyung Kim; Ho-Il Choi; Barry J Hoffer; Chaim G Pick; Nigel H Greig; Dong Seok Kim
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

Review 5.  Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms.

Authors:  Gohar Mushtaq; Jalaluddin A Khan; Taha A Kumosani; Mohammad A Kamal
Journal:  Saudi J Biol Sci       Date:  2014-05-23       Impact factor: 4.219

Review 6.  Cardiovascular autonomic neuropathies as complications of diabetes mellitus.

Authors:  Michael Kuehl; Martin J Stevens
Journal:  Nat Rev Endocrinol       Date:  2012-02-28       Impact factor: 43.330

Review 7.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

8.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

9.  PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.

Authors:  Taichi Nakamura; Tetsuhide Ito; Masahiko Uchida; Masayuki Hijioka; Hisato Igarashi; Takamasa Oono; Masaki Kato; Kazuhiko Nakamura; Koichi Suzuki; Robert T Jensen; Ryoichi Takayanagi
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

10.  Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6.

Authors:  Rozita Shirazi; Vilborg Palsdottir; Jim Collander; Fredrik Anesten; Heike Vogel; Fanny Langlet; Alexander Jaschke; Annette Schürmann; Vincent Prévot; Ruijin Shao; John-Olov Jansson; Karolina Patrycja Skibicka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.